• Pronase E Workflows for Ferroptosis Proteomics

  2026-09-28

  Pronase E broadens protein sample preparation for ferroptosis research, from protease-protection assays to peptide mapping and surface-protein analysis. This guide translates the CUL3–MTDH findings in triple-negative breast cancer into practical, controlled workflows while emphasizing optimization, quenching, and assay-specific controls.

• Dynasore for Ocular Nanoparticle Uptake Studies

  2026-09-28

  Use Dynasore to test whether dynamin activity contributes to nanoparticle uptake in corneal epithelial models—not to assume a single route explains all internalization. This workflow pairs a dose-controlled perturbation with physicochemical particle comparisons, viability controls, and orthogonal pathway evidence.

• Fluoxetine HCl: Motivation and Serotonin Workflows

  2026-09-27

  Use Fluoxetine HCl to probe serotonin transport and receptor signaling, then distinguish those molecular effects from changes in motivation and reward processing. A developmental-exposure study highlights why behavioral assays and nucleus accumbens opioid-circuit tests can complement serotonin-first experiments.

• MRT68921 and Energy-Aware Autophagy Assays

  2026-09-26

  MRT68921 is a potent dual ULK1/2 inhibitor for investigating autophagy initiation. This article explains how energy state can reshape assay interpretation—and how to distinguish direct ULK blockade from broader metabolic stress effects.

• (-)-JQ1: A Negative Control for BET Studies

  2026-09-25

  Use (-)-JQ1, the inactive JQ1 stereoisomer, to test whether cellular responses depend on BET bromodomain inhibition rather than solvent exposure or nonspecific treatment effects. This practical guide adapts that control strategy to HPV-associated head and neck cancer workflows, where transcriptional responses to BET inhibition can differ across cell lines.

• Developmental SSRIs, Motivation, and Accumbal MORs

  2026-09-25

  Emily Catherine Cambre’s 2026 Columbia University dissertation examines how developmental SSRI exposure affects reward-related behavior and reports a selective deficit in effortful motivation in mice. Its translational contribution includes adapting a progressive-ratio task for adolescent mice and identifying mu opioid receptor antagonism as a potential way to improve effortful responding in the developmental-exposure model, while highlighting important limits in the evidence provided.

• Cell-Surface RNA–Protein Domains and TAT Entry

  2026-09-24

  The study presents evidence that cell-surface RNA-binding proteins and glycoRNAs organize into nanoscale domains that can be disrupted by extracellular RNase. It links these domains to cell-penetrating peptide TAT interactions and uptake, expanding the proposed composition and functional organization of the cell surface.

• JXY Reprograms Macrophages in Colitis-Associated CRC

  2026-09-24

  Liu et al. report that Jiedu Xiaozheng Yin (JXY) reduced tumor burden and tissue injury in a mouse model of colitis-associated colorectal cancer while shifting macrophage markers toward an M1-like state. Their cell-based pathway-inhibitor experiments support a role for TLR4-associated signaling, although they do not establish that macrophage polarization alone explains the antitumor effect.

• Fluoxetine HCl: Mechanism and Research Use

  2026-09-23

  Fluoxetine HCl is a selective serotonin reuptake inhibitor used to probe serotonin-transporter and 5-HT2C-related signaling in neuroscience research. Developmental SSRI mouse findings link later motivational deficits to reward-circuit mechanisms, but they do not establish that every Fluoxetine HCl protocol produces those outcomes.

• Tioconazole Workflows for Antifungal Research

  2026-09-23

  Build reproducible Tioconazole experiments around ergosterol disruption, controlled formulation, and orthogonal fungal readouts. This guide connects practical in vitro antifungal assays with metabolic-state controls inspired by recent DNA-repair research, while clearly separating established evidence from exploratory ideas.

• One-step TUNEL FITC: Mechanism to Translation

  2026-09-22

  A mechanism-driven guide to using TUNEL fluorescence to interpret apoptosis in neurotoxicity, tissue, cultured-cell, and translational research workflows.

• Dantrolene sodium salt: RyR Workflows

  2026-09-22

  Dantrolene sodium salt provides a practical way to perturb ryanodine receptor signaling while preserving a clear mechanistic link to calmodulin-dependent calcium release. This guide translates that feature into reproducible workflows for calcium imaging, pancreatitis research, disease modeling, and hypothesis-driven CRISPR repair studies.

• Protease Inhibitor Cocktail for LAG-3–TCR Assays

  2026-09-21

  Preserve LAG-3, TCR, CD3ε, and phosphorylation-sensitive signals during extraction with an EDTA-free, broad-spectrum inhibitor workflow. This guide connects the product’s 100X DMSO format to Western blotting, co-immunoprecipitation, kinase assays, and proximity-focused immunology research.

• Cy3 NHS Ester (Non-Sulfonated) Protocol Guide

  2026-09-21

  Cy3 NHS ester (non-sulfonated) provides a reactive orange fluorophore for covalently labeling primary amines in proteins, peptides, and suitably modified nucleic acids. It is appropriate when DMSO, DMF, or another compatible organic co-solvent is acceptable, but it is not the first choice for strictly aqueous workflows or highly solvent-sensitive biomolecules.

• ASCH Proteins and N4-Acetylcytidine Processing

  2026-09-20

  Meng et al. define how the Escherichia coli ASCH-domain protein EcYqfB hydrolyzes free N4-acetylcytidine while showing that it does not remove ac4C from RNA. Structural comparisons with mouse EOLA1 and the human TRIP4-ASCH domain clarify how related proteins may recognize different nucleic-acid substrates, with direct implications for enzyme assays and RNA modification studies.

3676 records 3/246 page Previous Next 12345 下5页 Last page